Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783622 · ClinicalTrials.gov registry record · Phase 1
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, sponsored by Janux Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 18
- Study locations
NCT05783622: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, sponsored by Janux Therapeutics.
NCT05783622 is a Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma that is actively recruiting participants, run by Janux Therapeutics. The registered enrollment target is 130 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05783622, a Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, is actively recruiting participants, sponsored by Janux Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Conditions Studied
Interventions
- DRUG JANX008
Study Locations (18)
California
- City of Hope Medical Center - Duarte
- University of California, Davis Comprehensive Cancer Center - Sacramento
- University of California San Diego Moores Cancer Center - San Diego
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Health System - Detroit
Ohio
- The Christ Hospital Cancer Center - Cincinnati
- Ohio State University Hospital - Columbus
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas, MD Anderson Cancer Center - Houston
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT05783622 shows while recruiting
NCT05783622 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which JANX008 is the first listed.
NCT05783622 lists 18 locations in 12 states (California, Michigan, Ohio).
Frequently Asked Questions
What is clinical trial NCT05783622 about?
NCT05783622 is a clinical study titled "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies". This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma ...
What is the current status of trial NCT05783622?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2023-04-19. Estimated completion is 2027-10.
What conditions does trial NCT05783622 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Small-cell Lung Cancer.
What interventions are being tested in trial NCT05783622?
The interventions under investigation include: JANX008 (DRUG).
Who is sponsoring clinical trial NCT05783622?
This trial is sponsored by Janux Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05783622 being conducted?
This trial has 18 study locations across California, Georgia, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05783622's enrollment target sits among peer trials
130 210th of 454 higher than 242 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI